Amylyx Pharmaceuticals (AMLX) Shareholder Investigation

Shamis & Gentile, P.A. is investigating potential shareholder claims on behalf of Amylyx Pharmaceuticals, Inc. ("Amylyx Pharmaceuticals" or the "Company") (AMLX) against certain of its directors and officers for alleged breaches of fiduciary duties and other violations of law. Concerned shareholders are advised to contact the firm now.

The inquiry follows the filing of a class action complaint on February 9, 2024, which alleges that certain directors and officers of Amylyx Pharmaceuticals made materially false and misleading statements regarding the commercial prospects of Relyvrio, its drug to treat amyotrophic lateral sclerosis (ALS). According to the complaint, the Company overstated prescription rates, failed to disclose that patients were discontinuing treatment after six months and that new patient starts were declining. The complaint further alleges that Amylyx Pharmaceuticals restricted analyst access to prescription data, contributing to materially misleading public statements about the drug’s performance and demand.

On November 9, 2023, Amylyx reported rising discontinuation rates and lower-than-expected third-quarter results, revealing that only 60% of patients remained on therapy and prompting a 30% stock drop. In March 2024, the Company announced that Relyvrio failed its Phase III trial, leading to an additional 80% decline, and formally withdrew the drug on April 4, 2024. On September 30, 2025, a court allowed key allegations in the securities class action to proceed.

If you have held Amylyx Pharmaceuticals (NASDAQ: AMLX) since at least November 2022, you may be able to seek corporate reforms, the return of funds back to the Company, and a court approved incentive award for you, all at absolutely no cost.

Shamis & Gentile, P.A. stands out as an advocate for shareholders seeking corporate accountability and governance reforms. The firm is committed to pursuing derivative actions that benefit companies and their shareholders by recovering damages and implementing meaningful corporate governance improvements. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise, and resources enable the firm to resolve disputes in a wide range of matters, including derivative actions, class actions and complex commercial litigation.

Attorney advertising. Prior results do not guarantee similar outcomes.